What's in DBV Technologies's pipeline?

DBV Technologies has 7 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with DBV Technologies's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dbv-technologies.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

DBV Technologies — Portfolio Competitive Intelligence Brief

DBV Technologies pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DBV712	DBV712	phase 3	Epicutaneous immunotherapy (EPIT)		Immunology / Allergy
Viaskin Peanut 250µg	Viaskin Peanut 250µg	phase 3	Epicutaneous immunotherapy		Allergy

Therapeutic area mix

Allergy · 1
Immunology / Allergy · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for DBV Technologies:

Cite this brief

Drug Landscape (2026). DBV Technologies — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dbv-technologies. Accessed 2026-05-14.